Phase I/II Trial of MEK Inhibitor MEK162 in Patients with Relapsed and or Refractory Acute Myeloid Leukemia and Patients with Po
![Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/e6f64d15-2639-4910-be78-a2329618d1a9/bcp12497-fig-0002-m.jpg)
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library
![Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/906be1b9-651a-4b3a-abd1-22804627b337/bcp12497-fig-0001-m.jpg)